Home/Filings/4/0001562180-24-005867
4//SEC Filing

Etherington Robert Dee 4

Accession 0001562180-24-005867

CIK 0001822791other

Filed

Jul 29, 8:00 PM ET

Accepted

Jul 30, 9:03 AM ET

Size

10.3 KB

Accession

0001562180-24-005867

Insider Transaction Report

Form 4
Period: 2024-07-29
Etherington Robert Dee
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Stock Options (Right to buy)

    2024-07-29+27,32027,319 total
    Exercise: $3.00From: 2014-07-31Exp: 2024-07-30Common Stock (27,320 underlying)
  • Exercise/Conversion

    Common Stock

    2024-07-29$3.00/sh+27,320$81,96030,149 total
Holdings
  • Common Stock

    (indirect: By LLC)
    636
  • Common Stock

    (indirect: By Trust)
    1,250
Footnotes (6)
  • [F1]On July 11, 2024, the common stock of Clene Inc. underwent a 1-for-20 reverse stock split, resulting in the reporting person's ownership in the previously disclosed 56,593 shares of common stock being reduced to 2,829 shares.
  • [F2]On July 11, 2024, the common stock of Clene Inc. underwent a 1-for-20 reverse stock split, resulting in the reporting person's stock beneficial ownership in the previously disclosed 12,717 shares of common stock indirectly owned being reduced to 636 shares.
  • [F3]The securities are owned by RDE RX Ventures LLC. Mr. Etherington is the manager of RDE RX Ventures LLC. The shares owned by RDE RX Ventures LLC may also be deemed to be beneficially owned by Mr. Etherington.
  • [F4]On July 11, 2024, the common stock of Clene Inc. underwent a 1-for-20 reverse stock split, resulting in the reporting person's beneficial ownership in the previously disclosed 25,000 shares of common stock indirectly owned being reduced to 1,250.
  • [F5]The securities are owned by the Etherington Revocable Trust. Mr. Etherington is the co-trustee of the Etherington Revocable Trust. The shares owned by the Etherington Revocable Trust may be deemed to be beneficially owned by Mr. Etherington.
  • [F6]On July 11, 2024, the common stock of Clene Inc. underwent a 1-for-20 reverse stock split, resulting in the reporting person's stock option grant of 1,092,777 options to purchase common stock being reduced to 54,639 options. The exercise option price for these options was increased from $0.15 per share to $3.00 per share.

Issuer

Clene Inc.

CIK 0001822791

Entity typeother

Related Parties

1
  • filerCIK 0001835330

Filing Metadata

Form type
4
Filed
Jul 29, 8:00 PM ET
Accepted
Jul 30, 9:03 AM ET
Size
10.3 KB